Scroll for more

Product

 

AMITIZA®
(lubiprostone)

AMITIZA WITHIN ITALY

amitizuk

 

Click here for full Italian Summary of Product Characteristics for AMITIZA.

 

For medical information inquiries in Italy, contact: sucampoeu@druginfo.com.

 
 

AMITIZA®
(lubiprostone)

AMITIZA WITHIN THE
UNITED KINGDOM

amitizuk

 

Healthcare professionals, click here to learn more about AMITIZA and constipation.

Click here for full U.K. Summary of Product Characteristics for AMITIZA.

For medical information inquiries in the U.K., contact: 0800-756-3416.

 
 

AMITIZA®
(lubiprostone)

AMITIZA WITHIN AUSTRIA

amitizuk

 

Click here for full Austrian Summary of Product Characteristics for AMITIZA.

 

For medical information inquiries in Austria, contact: sucampoeu@druginfo.com.

 
 

AMITIZA®
(lubiprostone)

AMITIZA WITHIN GERMANY

amitizuk

 

Click here for full German Summary of Product Characteristics for AMITIZA.

 

For medical information inquiries in Austria, contact: sucampoeu@druginfo.com.

 
 

AMITIZA®
(lubiprostone)

AMITIZA WITHIN SWITZERLAND

amitiza-swiss

 

Click here for full Swiss Product Information for AMITIZA.

 

For medical information inquiries in Switzerland, contact the Takeda CH Call Center: +41-0-55-451-5200 or by email at info@takeda.ch.

 
 

AMITIZA®
(lubiprostone)

AMITIZA WITHIN IRELAND

amitizuk

 

Click here for full Irish Summary of Product Characteristics for AMITIZA.

 

For medical information inquiries in Ireland, contact: sucampoeu@druginfo.com.

 
 

AMITIZA®
(lubiprostone)

AMITIZA WITHIN BELGIUM

amitizuk

 

Click here for full Belgian Dutch Summary of Product Characteristics for AMITIZA.

Click here for full Belgian French Summary of Product Characteristics for AMITIZA.

 

For medical information inquiries in Belgium, contact: sucampoeu@druginfo.com.

 
 

AMITIZA®
(lubiprostone)

AMITIZA WITHIN THE NETHERLANDS

amitizuk

 

Click here for full Dutch Summary of Product Characteristics for AMITIZA.

 

For medical information inquiries in Netherlands, contact: sucampoeu@druginfo.com.

 
 

AMITIZA®
(lubiprostone)

AMITIZA WITHIN LUXEMBOURG

amitizuk

 

Click here for full Luxembourg Dutch Summary of Product Characteristics for AMITIZA.

Click here for full Luxembourg French Summary of Product Characteristics for AMITIZA.

Click here for full Luxembourg German Summary of Product Characteristics for AMITIZA.

 

For medical information inquiries in Luxembourg, contact: sucampoeu@druginfo.com.

 
 

AMITIZA®
(lubiprostone)

AMITIZA WITHIN SPAIN

amitizuk

 

Click here for full Spanish Summary of Product Characteristics for AMITIZA.

 

For medical information inquiries in Netherlands, contact: sucampoeu@druginfo.com.

 
 

The product websites presented here are intended for use in Europe only. There may be different regulations in other countries that may require referencing different information. If you require product information for a country other than Europe, please select a region below.

United States Asia Europe

 
Contact Us
 
Tel: +1-301-961-3400
 

Sucampo Pharmaceuticals, Inc. is focused on the development and commercialization of specialized medicines that meet major unmet medical needs of patients worldwide. Sucampo has two marketed products – AMITIZA, its lead product, and RESCULA – and a late-stage pipeline of product candidates in clinical development for orphan disease areas. VTS-270 is a mixture of 2-hydroxypropyl-B-cyclodextrins with a specific compositional fingerprint that has been granted orphan designation in the U.S. and Europe and is in a pivotal Phase 2/3 clinical trial for the treatment of Niemann-Pick Disease Type C-1. Sucampo has an option for the North American rights to CPP1- x/sulindac, which is in Phase 3 development for the treatment of familial adenomatous polyposis and has been granted orphan drug designation in the U.S. A global company, Sucampo is headquartered in Rockville, Maryland, and has operations in Japan and Switzerland.